Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +0.18% 1,367.00p 1,363.00p 1,367.50p 1,372.50p 1,366.00p 1,366.00p 528 08:04:47
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,433.4 -546.4 -260.1 - 3,317.42

Hikma Pharmaceuticals Share Discussion Threads

Showing 1001 to 1024 of 1025 messages
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
DateSubjectAuthorDiscuss
22/5/2018
12:58
Stuff them too.
bantam175
22/5/2018
06:29
Is it not Barclay's clients?
r ball
21/5/2018
18:08
Barclays seem to have a big short outstanding. Stuff 'em.
bantam175
18/5/2018
15:58
Give the run up to the trading statement I view a positive finish today as encouraging. No need to sell and every reason to add. Suspect a few upgrades are around the corner.
r ball
18/5/2018
14:49
I've just filtered the chinaman. Got tired of his constant repetition. Good stories don't need to be broadcast every hour or so.
investordave
18/5/2018
14:43
LONDON (Alliance News) - FTSE 250-listed Hikma Pharmaceuticals PLC said on Friday the first four months of 2018 brought an "encouraging" start to the year. The Injectables business saw good demand for its marketed products in Europe, and new launches drive revenue growth in the Middle East and North Africa. In the US the business has found itself able to meet increased demand with new product launches in the year to date. Hikma expects Injectables revenue to be within the range of USD750 million to USD800 million for 2018, and the operating margin to be at the low to mid 30s. Injectables revenue for 2017 was USD776 million. The group's Generics business saw a good start to the year despite the US market remaining tough, Hikma said. The segment is on track to consolidate its manufacturing and distribution facilities in the second half of the year, and the repeat clinical endpoint study for Advair Diskus is proceeding as planned. Revenue from Generics is forecast to be in the range of USD550 million to USD600 million, and the operating margin in the low single digits. Generic revenue for 2017 was USD615 million Finally, Hikma said it has seen sales growth and new launches for its Branded division, but expects its performance to be more weighted towards the second half of 2018. Revenue growth for the full year is expected to be in the mid-single digits on a constant currency basis. For 2017, the Branded unit reported revenue of USD536 million. "The year is off to an encouraging start. In the first four months, our Injectables, Generics and Branded businesses are benefiting from our broad product portfolio and recent product launches. Our efforts to reduce costs across the group are on track and we continue to focus on enhancing and investing in our pipeline. Our cash position remains very healthy and our balance sheet is strong. Altogether, these factors reinforce our positive outlook for the Group and enable us to reiterate our guidance for the full year," said Chief Executive Officer Siggi Olafsson
broadwood
17/5/2018
08:44
Share price movement triggered by genetics news? Has there been a clamp down on Indian competitors?
r ball
16/5/2018
14:23
Continuing progress on recent rec.
broadwood
08/5/2018
09:03
Maybe some of the takeover activity in the sector is spilling over here.
broadwood
02/5/2018
18:30
Nice and steady before it heads to £14 IMO
gerrym two
01/5/2018
22:37
2000p is achievable after FDA approval is obtained in 2019. I am hoping 2400p by end of 2019.
karateboy
30/4/2018
11:10
Shorters back on board again now. Nothing personal but here's hoping they get their fingers burnt. Back to 2000p and the ftse 100 by end of year would be nice.
bantam175
28/4/2018
21:29
SP is consolidating very well. I wounder if next stop will be £15.
karateboy
24/4/2018
22:58
Buying op. Sentiment change and with ex Teva guy in charge....well
r ball
23/4/2018
20:46
Meant Clinigen
r ball
23/4/2018
20:45
Doubt it or clingier would have risen too. This. was announced on Friday and the shortage was flagged in July 2017. The FDA website is worth looking at
r ball
23/4/2018
19:49
Strong rise today could be down to this. Hikma Subsidiary West-Ward Launches Dexrazoxane For Injection for heart problems.
broadwood
20/4/2018
18:41
Upgrade today...
r ball
20/4/2018
09:00
M&A activity rife in the sector. Could this be next?
broadwood
19/4/2018
12:42
Expected the results to be better than this. Nothing disastrous though. Actually they're not bad considering.
isstaaz
12/4/2018
20:31
Back to 1250 territory tomorrow but this might spike even higher....Shire speculation etc could move the sector IMO
gerrym two
12/4/2018
20:12
Intraday drops are fading towards the close.
r ball
10/4/2018
10:04
Showing welcome strength this morning.
broadwood
29/3/2018
20:30
It's not really news. This is what they do. What is news is a brand new generic...
r ball
Chat Pages: 41  40  39  38  37  36  35  34  33  32  31  30  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180523 07:19:50